Emergent BioSolutions Inc. (FRA:ER4)

Market Cap	487.47M
Revenue (ttm)	672.38M
Net Income (ttm)	64.69M
Shares Out	n/a
EPS (ttm)	1.15
PE Ratio	7.54
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234
Average Volume	22
Open	9.43
Previous Close	9.60
Day's Range	9.43 - 9.63
52-Week Range	3.75 - 11.22
Beta	n/a
RSI	56.92
Earnings Date	Mar 5, 2026

About Emergent BioSolutions

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 900
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ER4

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Financial numbers in USD